Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV002250019 | SCV002516485 | pathogenic | Fabry disease | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003403751 | SCV004110958 | likely pathogenic | GLA-related disorder | 2023-04-04 | criteria provided, single submitter | clinical testing | The GLA c.782delG variant is predicted to result in a frameshift and premature protein termination (p.Gly261Valfs*8). This variant was reported in male with classic Fabry disease, with α‐gal A enzyme activity in leukocytes <5% of normal activity (Nampoothiri et al. 2020. PubMed ID: 33204599). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in GLA are expected to be pathogenic. This variant is interpreted as likely pathogenic. |